Affordable Access

Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.

Authors
  • Teicher, B A
  • Sotomayor, E A
  • Huang, Z D
Type
Published Article
Journal
Cancer research
Publication Date
Dec 01, 1992
Volume
52
Issue
23
Pages
6702–6704
Identifiers
PMID: 1384969
Source
Medline
License
Unknown

Abstract

The formation of a blood supply (angiogenesis) is critical to the growth of solid tumors. The naturally occurring steroid tetrahydrocortisol, the synthetic cyclodextrin derivative beta-cyclodextrin tetradecasulfate, and the tetracycline derivative minocycline have antiangiogenic activity. Tetrahydrocortisol and beta-cyclodextrin tetradecasulfate in a 1:1 molar ratio by continuous infusion over 14 days and minocycline administered i.p. over 14 days from day 4 to day 18 postimplantation of the Lewis lung carcinoma significantly increased the growth delay of the primary tumor after treatment with cis-diamminedichloroplatinum(II), melphalan, cyclophosphamide, Adriamycin, bleomycin, and radiation therapy administered in standard regimens. Addition of the antiangiogenic agents to treatment with the cytotoxic therapies not only reduced the number of lung metastases formed from the primary tumor but also reduced the number of large metastases. Five of 12 animals treated with the antiangiogenic modulators and cyclophosphamide were long-term survivors (> 120 days). Thus, antiangiogenic therapies can potentiate the efficacy of standard anticancer therapies.

Report this publication

Statistics

Seen <100 times